Pricing Log in Create free account
Saturday 17 October 2026 Export MRK’s income statement to Excel — free account

Merck & Co., Inc.

MRK Healthcare Drug Manufacturers General

Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024. In the quarter to June 2026, revenue grew 5.07%, EPS fell 130.7%, free cash flow grew 77.0% and total debt rose 50.4%, each against the same quarter a year earlier. Member of the S&P 500 and Dow Jones; dividend growth for twenty-five consecutive years, revenue growth for five.

145.95 0.76 +0.52%
Market cap
$358.2B
P/E
117×
Fwd P/E
53.9×
Dividend yield
2.33%
F-score
4/9
Altman Z
3.77
Beneish M
−2.27
Dividend safety
74/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Merck & Co., Inc. (MRK) Operating cash flow

Alert me on Operating cash flow

Merck & Co., Inc.'s operating cash flow for fiscal 2025 was $16.5B, down 23.3% from $21.5B in fiscal 2024. Over the twelve months to 30 June 2026 it was $20.0B. Over the past ten years it has ranged from $6.5B (fiscal 2017) to $21.5B (fiscal 2024); the current reading is higher than 82% of that period. Merck & Co., Inc. ranks 5th of 21 Drug Manufacturers General companies by operating cash flow.

Operating cash flow, annual

Embed this chart

Annual newest first

Period Operating cash flow Change
FY2025 $16.5B (23.27%)
FY2024 $21.5B 65.06%
FY2023 $13.0B (31.89%)
FY2022 $19.1B 45.52%
FY2021 $13.1B 72.27%
FY2020 $7.6B (14.26%)
FY2019 $8.9B (18.66%)
FY2018 $10.9B 69.31%
FY2017 $6.5B (37.83%)
FY2016 $10.4B (17.24%)

Quarterly newest first

Period Operating cash flow Change
Jun 2026 $5.4B 37.06%
Mar 2026 $3.9B 37.14%
Dec 2025 $2.9B (63.47%)
Sep 2025 $7.8B 137.53%
42 more quarters

Against its own ten years

Low $6.5B High $21.5B
Ten-year median $12.5B
Current reading's percentile 82

Operating cash flow against peers

Company Operating cash flow
JNJ Johnson & Johnson compare $27.6B
NVO Novo Nordisk A/S compare $20.4B
MRK Merck & Co., Inc. $20.0B
ABBV AbbVie Inc. compare $19.5B
NVS Novartis AG compare $18.4B
AZN AstraZeneca PLC compare $13.7B
GILD Gilead Sciences, Inc. compare $13.6B
PFE Pfizer Inc. compare $13.4B
AMGN Amgen Inc. compare $12.5B

What Operating cash flow is

Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.

Reported line item

The full definition of Operating cash flow →

More on MRK